Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 691 to 700 of 2599 total matches.

Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms

   
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019  (Issue 1575)
that are chemically similar to endogenous hormones such as estradiol and progesterone.1 FDA-approved formulations ...
The FDA has approved Bijuva (TherapeuticsMD), a fixed-dose combination of estradiol and progesterone, for oral treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with an intact uterus. The manufacturer is marketing Bijuva as "the first and only FDA-approved combination of bio-identical estradiol and bio-identical progesterone in a single daily oral capsule".
Med Lett Drugs Ther. 2019 Jul 1;61(1575):99-101 |  Show IntroductionHide Introduction

Expanded Table: Drugs for Malaria Prophylaxis (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019  (Issue 1575)
Pediatric 1 adult tab (250/100 mg) once/day 5-8 kg: ½ ped tab/day (1 ped tab is 62.5/25 mg) 9-10 kg ...
View the Expanded Table: Drugs for Prophylaxis of Malaria
Med Lett Drugs Ther. 2019 Jul 1;61(1575):e104-5 |  Show IntroductionHide Introduction

Romosozumab (Evenity) for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019  (Issue 1573)
(Tymlos) and teriparatide (Forteo) were approved earlier.1 Other drugs used for treatment ...
The FDA has approved romosozumab-aqqg (Evenity – Amgen), a sclerostin inhibitor, for once-monthly subcutaneous (SC) treatment of osteoporosis in postmenopausal women who are at high risk for fracture (history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or cannot tolerate other drugs for this indication. Romosozumab is the first sclerostin inhibitor to be approved in the US and the third drug for treatment of postmenopausal osteoporosis that stimulates bone formation; the parathyroid hormone (PTH) receptor agonists abaloparatide (Tymlos) and...
Med Lett Drugs Ther. 2019 Jun 3;61(1573):83-6 |  Show IntroductionHide Introduction

Prucalopride (Motegrity) for Chronic Idiopathic Constipation

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019  (Issue 1573)
of anal blockage or incomplete evacuation, and a need for manual maneuvers to aid defecation.1 ...
The FDA has approved the 5-HT4 receptor agonist prucalopride (Motegrity – Shire) for treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride is the only drug currently approved in the US for treatment of CIC that stimulates colonic peristalsis. It has been available in Europe and Canada for several years.
Med Lett Drugs Ther. 2019 Jun 3;61(1573):86-8 |  Show IntroductionHide Introduction

Risankizumab (Skyrizi) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019  (Issue 1573)
. The first year of treatment costs $88,500. Its long-term safety is unknown. Table 1. Pharmacology Class ...
The FDA has approved the interleukin (IL)-23 antagonist risankizumab-rzaa (Skyrizi – Abbvie) for treatment of moderate to severe plaque psoriasis in adults. Risankizumab is the third IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) and tildrakizumab (Ilumya) were approved earlier.
Med Lett Drugs Ther. 2019 Jun 3;61(1573):81-3 |  Show IntroductionHide Introduction

Expanded Table: Some Drugs for Chronic Idiopathic Constipation (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019  (Issue 1573)
, mean spontaneous bowel movement frequency in week 1 was 5.7-5.9 with the drug and 3.5-4.0 ...
View the Expanded Table: Some Drugs for Chronic Idiopathic Constipation
Med Lett Drugs Ther. 2019 Jun 3;61(1573):e88-90 |  Show IntroductionHide Introduction

PrabotulinumtoxinA (Jeuveau) for Frown Lines

   
The Medical Letter on Drugs and Therapeutics • May 20, 2019  (Issue 1572)
to be approved in the US for this indication (see Table 1). It has been available in South Korea as Nabota ...
The FDA has approved prabotulinumtoxinA-xvfs (Jeuveau – Evolus) for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity. Jeuveau is the fourth botulinum toxin product to be approved in the US for this indication (see Table 1). It has been available in South Korea as Nabota since 2014.
Med Lett Drugs Ther. 2019 May 20;61(1572):79-80 |  Show IntroductionHide Introduction

Omadacycline (Nuzyra) - A New Tetracycline Antibiotic

   
The Medical Letter on Drugs and Therapeutics • May 20, 2019  (Issue 1572)
to tetracyclines. Pronunciation Key Omadacycline: oh mad" a sye' kleen Nuzyra: new zye' rah Table 1 ...
The FDA has approved omadacycline (Nuzyra – Paratek), a semisynthetic tetracycline derivative, for once-daily IV and oral treatment of community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSIs) in adults.
Med Lett Drugs Ther. 2019 May 20;61(1572):74-7 |  Show IntroductionHide Introduction

Inhaled Levodopa (Inbrija) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • May 20, 2019  (Issue 1572)
-B) inhibitor.1 Levodopa is absorbed in the proximal small intestine. In patients with advanced PD ...
The FDA has approved Inbrija (Acorda), an orally inhaled dry-powder formulation of levodopa, for intermittent treatment of "off" episodes in patients with Parkinson's disease (PD) being treated with carbidopa/levodopa (Sinemet, and others).
Med Lett Drugs Ther. 2019 May 20;61(1572):73-4 |  Show IntroductionHide Introduction

Emicizumab (Hemlibra) for Subcutaneous Prophylaxis in Hemophilia A

   
The Medical Letter on Drugs and Therapeutics • May 20, 2019  (Issue 1572)
-linked recessive deficiency of coagulation factor VIII that occurs in about 1 in 5000 male births ...
The FDA has approved emicizumab-kxwh (Hemlibra – Genentech), a subcutaneously injected, factor IXa- and X-directed antibody, for routine prophylaxis to prevent or reduce bleeding episodes in patients with hemophilia A. Emicizumab is not recommended for treatment of bleeding.
Med Lett Drugs Ther. 2019 May 20;61(1572):77-9 |  Show IntroductionHide Introduction